-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, TsvwrkNBnG5jbIXZqnBGZ+PtFG9cTSuXWEDn1IY5u0RwAAdTWvEf07zjAdwhtKud zKYpGp/bdofrjAbb3Fi9+Q== 0000947871-01-500596.txt : 20010821 0000947871-01-500596.hdr.sgml : 20010821 ACCESSION NUMBER: 0000947871-01-500596 CONFORMED SUBMISSION TYPE: 424B3 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20010820 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MERRILL LYNCH PIERCE FENNER & SMITH INC CENTRAL INDEX KEY: 0000728612 STANDARD INDUSTRIAL CLASSIFICATION: ASSET-BACKED SECURITIES [6189] STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B3 SEC ACT: 1933 Act SEC FILE NUMBER: 333-89355 FILM NUMBER: 1718958 BUSINESS ADDRESS: STREET 1: NORTH TOWER WORLD FINANCIAL CENTER STREET 2: NORTH TOWER WORLD FINANCIAL CENTER 5TH F CITY: NEW YORK STATE: NY ZIP: 10281-1323 BUSINESS PHONE: 2124496202 MAIL ADDRESS: STREET 1: WORLD FINANCIAL CENTER STREET 2: NORTH TOWER 23RD FL CITY: NEW YORK STATE: NY ZIP: 10281-1323 424B3 1 f424b3_081701-biotech.txt PROSPECTUS SUPPLEMENT PROSPECTUS SUPPLEMENT FILED PURSUANT TO RULE NO. 424(b)(3) (To Prospectus dated January 23, 2001) REGISTRATION NO. 333-89355 [LOGO](sm) 1,000,000,000 Depositary Receipts Biotech HOLDRS(sm) Trust This prospectus supplement supplements information contained in the prospectus dated January 23, 2001, which updated the original prospectus dated November 22, 1999 relating to the sale of up to 1,000,000,000 depositary receipts by the Biotech HOLDRS(SM) Trust The share amounts specified in the table on page 11 of the base prospectus shall be replaced with the following: Primary Share Trading Name of Company (1) Ticker Amounts Market - --------------------------------------------- ------ ------- ------- Affymetrix, Inc. AFFX 4 Nasdaq NMS Alkermes, Inc. ALKS 4 Nasdaq NMS Amgen Inc. AMGN 46 Nasdaq NMS Applera Corporation--Applied Biosystems Group ABI 18 NYSE Applera Corporation--Celera Genomics Group CRA 4 NYSE Biogen, Inc. BGEN 13 Nasdaq NMS Chiron Corporation CHIR 16 Nasdaq NMS Enzon, Inc. ENZN 3 Nasdaq NMS Genentech, Inc. DNA 44 NYSE Genzyme Corporation GENZ 14 Nasdaq NMS Gilead Sciences, Inc. GILD 8 Nasdaq NMS Human Genome Sciences, Inc. HGSI 8 Nasdaq NMS ICOS Corporation ICOS 4 Nasdaq NMS IDEC Pharmaceuticals Corporation IDPH 12 Nasdaq NMS Immunex Corporation IMNX 42 Nasdaq NMS MedImmune, Inc. MEDI 15 Nasdaq NMS Millennium Pharmaceuticals, Inc. MLNM 12 Nasdaq NMS QLT Inc. QLTI 5 Nasdaq NMS Sepracor Inc. SEPR 6 Nasdaq NMS Shire Pharmaceuticals Group p.l.c.(1) SHPGY 6.8271 Nasdaq NMS - -------------- (1) On May 11, 2001, BioChem Pharma Inc. completed its merger with Shire Pharmaceuticals Group p.l.c. As a result of the merger, each share of BioChem Pharma was exchanged for 0.7586 share of Shire Pharmaceuticals.The share amount of Shire Pharmaceuticals represented by a round-lot of 100 Biotech HOLDRS is now 6.8271. The share amounts listed in the table above reflect all previous stock splits, dividends and business combination transactions. The date of this prospectus supplement is June 30, 2001. -----END PRIVACY-ENHANCED MESSAGE-----